3.195USD+0.47%Mkt Cap: 13.84M USDP/E: —Last update: 2026-05-26
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periph…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap13.84M USD
Enterprise Value10.86M USD
Revenue (TTM)1.99M USD
Gross Profit1.03M USD
Net Income (TTM)-3.53M USD
Revenue/Share0.5550 USD
Last Price3.195 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.41
PEG—
EV/EBITDA—
EV/Revenue5.45
P/S6.87
P/B1.97
EPS (TTM)-1.31
EPS (Forward)-1.31
52W Range
1.02729% of range8.480
52W High8.480 USD
52W Low1.027 USD
Profitability
Gross Margin51.88%
Oper. Margin-337.43%
EBITDA Margin0.00%
Profit Margin-170.11%
ROE-38.83%
ROA-35.33%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.31M USD
CapEx (TTM)—
FCF Margin-129.91%
FCF Yield-18.71%
Net Debt-2.82M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio1.80
Quick Ratio1.65
Book Value/Sh1.601 USD
Cash/Share0.6520 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateMay 16, 2023
Analyst Consensus
Rating—
Target (Mean)8.000 USD
Target Range8.000 USD – 8.000 USD
# Analysts1
Ownership
Shares Out.4.33M
Float3.58M
Insiders24.26%
Institutions4.17%
Short Interest
Short Ratio0.0d
Short % Float1.58%
Short % Out.1.31%
Shares Short56.62K
Short (prev mo.)113.45K
Technical
SMA 502.805 (+13.9%)
SMA 2002.083 (+53.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)110.49K
Avg Vol (10d)63.51K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—